These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 8191475

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The use of health economic information by reimbursement authorities.
    Drummond MF.
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
    Grocott R.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
    [Abstract] [Full Text] [Related]

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE, Kleijnen J.
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ.
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [Abstract] [Full Text] [Related]

  • 14. [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].
    Schlander M.
    Med Klin (Munich); 2005 Jun 15; 100(6):314-24. PubMed ID: 15968483
    [Abstract] [Full Text] [Related]

  • 15. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R.
    Lakartidningen; 2005 Jun 15; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract] [Full Text] [Related]

  • 16. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J, Kivi I, Linnosmaa I.
    Health Policy; 2005 Nov 15; 74(3):235-46. PubMed ID: 16226136
    [Abstract] [Full Text] [Related]

  • 17. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A, Martin P.
    Stud Hist Philos Biol Biomed Sci; 2006 Sep 15; 37(3):583-601. PubMed ID: 16980196
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb 15; 13(69):32-6. PubMed ID: 15055226
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.